Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors.
In an in vitro model for mitogenic activity in cloned Chinese hamster ovary (CHO) cells expressing rat dopamine D2 or D3 receptors, the EC50D2/EC50D3 ratios for the agonists, apomorphine, (+)-3-hydroxy-N-n-propyl-phenylpiperidine ((+)-3-PPP), quinpirole, R-(+)-7-hydroxy-2-(di-n-propylamino)tetralin (R-(+)-7-OH-DPAT) and pramipexole (SND919) were found to be 0.36, 0.41, 1.3, 3.7 and 7.0, respectively. In locomotor activity experiments with actively exploring rats, the more dopamine D3 preferring agonists, R-(+)-7-OH-DPAT and pramipexole, were most efficacious to reduce locomotion. The hypoactivity was also observed at doses that did not affect brain dopamine synthesis rate (DOPA accumulation) or release (measured in in vivo dialysis experiments). In contrast, for apomorphine, (+)-3-PPP and quinpirole there was a closer correlation between doses that reduced exploratory activity and doses that reduced brain dopamine release and synthesis. The present data support the hypothesis that the functional dopamine D3 receptor is a postsynaptic receptor inhibitory on rat locomotion.
Department of Pharmacology, University of Göteborg, Sweden.
K
K
Svensson
A
A
Carlsson
R M
RM
Huff
T
T
Kling-Petersen
N
N
Waters
D000704:Analysis of Variance; D000818:Animals; D001058:Apomorphine / Q000008:administration & dosage / Q000494:pharmacology; D052160:Benzothiazoles; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D004295:Dihydroxyphenylalanine / Q000378:metabolism; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004873:Ergolines / Q000008:administration & dosage / Q000494:pharmacology; D008297:Male; D017551:Microdialysis; D008934:Mitogens / Q000633:toxicity; D009043:Motor Activity / Q000187:drug effects*; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology; D000077487:Pramipexole; D019257:Quinpirole; D051381:Rats; D017207:Rats, Sprague-Dawley; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology*; D017448:Receptors, Dopamine D2 / Q000819:agonists / Q000502:physiology*; D050637:Receptors, Dopamine D3; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage / Q000494:pharmacology; D013844:Thiazoles / Q000008:administration & dosage / Q000494:pharmacology; D014162:Transfection
D052160:Benzothiazoles; D018491:Dopamine Agonists; C493595:Drd3 protein, rat; D004873:Ergolines; D008934:Mitogens; D010880:Piperidines; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D013764:Tetrahydronaphthalenes; D013844:Thiazoles; D019257:Quinpirole; D004295:Dihydroxyphenylalanine; D000077487:Pramipexole; C026539:preclamol; D001058:Apomorphine; C031349:7-hydroxy-2-N,N-dipropylaminotetralin